Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey

TY - JOUR

T1 - Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey

AU - Passweg, Jakob R

AU - Baldomero, Helen

AU - Chabannon, Christian

AU - Corbacioglu, Selim

AU - de la Cámara, Rafael

AU - Dolstra, Harry

AU - Glass, Bertram

AU - Greco, Raffaella

AU - Mohty, Mohamad

AU - Neven, Bénédicte

AU - Peffault de Latour, Régis

AU - Perić, Zinaida

AU - Snowden, John A

AU - Yakoub-Agha, Ibrahim

AU - Sureda, Anna

AU - Kröger, Nicolaus

AU - European Society for Blood and Marrow Transplantation (EBMT)

N1 - © 2022. The Author(s).

PY - 2022/5

Y1 - 2022/5

N2 - In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT -6.5%, allogeneic HCT -5.1%, autologous HCT -7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.

AB - In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT -6.5%, allogeneic HCT -5.1%, autologous HCT -7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.

KW - COVID-19

KW - Europe/epidemiology

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Neoplasms/etiology

KW - Pandemics

KW - SARS-CoV-2

KW - Transplantation, Homologous

U2 - 10.1038/s41409-022-01604-x

DO - 10.1038/s41409-022-01604-x

M3 - SCORING: Journal article

C2 - 35194156

VL - 57

SP - 742

EP - 752

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 5

ER -